Oteseconazole: A Review

  • Neha Research Scholar, Arya College of Pharmacy
  • Sampat Kumar Research Scholar, Arya College of Pharmacy
  • Vani Madaan Research Scholar, Faculty of Pharmacy, BN University, Udaipur
  • Dr. Vandana Sharma Professor & Principal, Arya College of Pharmacy
  • Dr. Mukesh Sharma Professor, Arya College of Pharmacy
  • Shankar Lal Soni Research Scholar, Faculty of Pharmacy, BN University, Udaipur
  • Ashok Kumar Sharma Research Scholar, Faculty of Pharmacy, BN University, Udaipur
Keywords: oteseconazole, vaginal infection, antifungal drugs, candida, vaginitis

Abstract

Many women are affected by vaginal fungal infections, also called yeast infections.  Vulvovaginal candidiasis (VVC) is a common fungal infection caused by Candida species, predominantly Candida albicans. RVVC compromises with women’s life. It causes symptoms – such as itching, pain, dyspareunia, dysuria, and leucorrhea2-4. Oteseconazole – a novel, oral, selective fungal cytochrome P450 enzyme 51 inhibitor, designed to avoid off-target toxicities. In clinical studies to date, oteseconazole has demonstrated impressive efficacy, a positive tolerability profile and hope for a superior RVVC treatment option. Fungal infection comes in different form like –ringworm athelets foot, toenail fungus, yeast infection and jock itch. Yeast infection of vagina and tissue at opening of vagina. Antifungal is used to treat and prevent mycosis. In this article we studied about the new FDA approved drug for vaginal yeast infection.

Published
2022-09-15
How to Cite
Neha, Kumar, S., Madaan, V., Sharma, D. V., Sharma, D. M., Lal Soni, S., & Kumar Sharma, A. (2022). Oteseconazole: A Review. Journal of Biomedical and Pharmaceutical Research, 11(5). https://doi.org/10.32553/jbpr.v11i5.918
Section
Articles

Most read articles by the same author(s)